post-commercialization trials for a better quality of life
The anti-HIV drugs we daily take came on the market long ago : in 1987 for AZT, and in 1996 for the protease inhibitors. The laboratories undertook the 3 necessary tests before the drugs were allowed to be distributed: phase 1, which concerns biological and clinical resistance, toxicity and dosage; phase 2 - medical efficacy and optimal dosage; and phase 3 - often a comparative study of the effective results of the drugs, including side effects... At the end of this third study permission to distribute the drugs is granted.
